Advertisement
BCRX vs CLDX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a Hold and CLDX is a StrongBuy.
BCRX's Indicator enters downward trend
The Aroon Indicator for BCRX entered a downward trend on October 22, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 201 similar instances where the Aroon Indicator formed such a pattern. In 161 of the 201 cases the stock moved lower. This puts the odds of a downward move at 80%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BCRX as a result. In 76 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for BCRX turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 40 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BCRX's RSI Oscillator exited the oversold zone, 31 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.376) is normal, around the industry mean (10.407). P/E Ratio (-5.763) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (2.097) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. BCRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
CLDX's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for CLDX turned positive on October 19, 2026. Looking at past instances where CLDX's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CLDX's RSI Indicator exited the oversold zone, 25 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 59 cases where CLDX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
Following a +10.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLDX advanced for three days, in 206 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
CLDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for CLDX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. CLDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.184) is normal, around the industry mean (2.973). P/E Ratio (-6.660) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. CLDX's P/S Ratio (10000.000) is very high in comparison to the industry average of (438.009).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
BCRX | CLDX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 66 | 62 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 14 Undervalued | 98 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 62 | 64 | |
P/E GROWTH RATING 1..100 | 98 | 22 | |
SEASONALITY SCORE 1..100 | 90 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BCRX's Valuation (14) in the Biotechnology industry is significantly better than the same rating for CLDX (98). This means that BCRX’s stock grew significantly faster than CLDX’s over the last 12 months.
BCRX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CLDX (100). This means that BCRX’s stock grew similarly to CLDX’s over the last 12 months.
CLDX's SMR Rating (98) in the Biotechnology industry is in the same range as BCRX (100). This means that CLDX’s stock grew similarly to BCRX’s over the last 12 months.
BCRX's Price Growth Rating (62) in the Biotechnology industry is in the same range as CLDX (64). This means that BCRX’s stock grew similarly to CLDX’s over the last 12 months.
CLDX's P/E Growth Rating (22) in the Biotechnology industry is significantly better than the same rating for BCRX (98). This means that CLDX’s stock grew significantly faster than BCRX’s over the last 12 months.
| BCRX | CLDX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 86% | 1 day ago 74% |
| Stochastic ODDS (%) | 1 day ago 82% | 1 day ago 76% |
| Momentum ODDS (%) | 1 day ago 80% | N/A |
| MACD ODDS (%) | 1 day ago 73% | 1 day ago 78% |
| TrendWeek ODDS (%) | 1 day ago 81% | 1 day ago 79% |
| TrendMonth ODDS (%) | 1 day ago 80% | 1 day ago 79% |
| Advances ODDS (%) | N/A | 3 days ago 77% |
| Declines ODDS (%) | 2 days ago 79% | 1 day ago 78% |
| BollingerBands ODDS (%) | N/A | 1 day ago 71% |
| Aroon ODDS (%) | 1 day ago 80% | 1 day ago 83% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BCRX’s FA Score shows that 1 FA rating(s) are green while CLDX’s FA Score has 1 green FA rating(s).
- BCRX’s FA Score: 1 green, 4 red.
- CLDX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BCRX’s TA Score shows that 2 TA indicator(s) are bullish while CLDX’s TA Score has 5 bullish TA indicator(s).
- BCRX’s TA Score: 2 bullish, 4 bearish.
- CLDX’s TA Score: 5 bullish, 2 bearish.
Price Growth
BCRX (@Pharmaceuticals: Generic) experienced а -2.99% price change this week, while CLDX (@Biotechnology) price change was +0.14% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.00%. For the same industry, the average monthly price growth was -9.86%, and the average quarterly price growth was +9.31%.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
BCRX is expected to report earnings on Nov 02, 2026.
CLDX is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-3.00% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DOCK | 25.95 | 0.27 | +1.04% |
| Corgi Ports, Rail & Freight ETF (DOCK) | |||
| BNDS | 47.07 | -0.10 | -0.22% |
| Infrastructure Capital Bond Income ETF | |||
| RNRG | 31.39 | -0.29 | -0.92% |
| Global X Renewable Energy Producers ETF (RNRG) | |||
| CHPY | 57.36 | -3.87 | -6.32% |
| YieldMax Semiconductor Portfolio Option Income ETF (CHPY) | |||
| EUV | 20.08 | -1.99 | -9.02% |
| Corgi Lithography & Semiconductor Photonics ETF (EUV) | |||